Is there a role for immune and anti-inflammatory therapy in type 2 diabetes?

T. Sathyapalan, S. L. Atkin

Research output: Contribution to journalReview article

11 Citations (Scopus)


There is a growing body of evidence to suggest that type 2 diabetes is associated with a generalised activation of the innate immune system, in which there is a chronic low-grade inflammation. Further evidence for roles of inflammation in type 2 diabetes comes from clinical studies using either anti-inflammatory approaches or biological agents that target specific proinflammatory cytokine pathways to improve parameters of glucose control especially with IL-1β (Interleukin 1 β) antagonism and salsalate (non-acetylated prodrug of salicylate) treatment. In this review, recent evidence implicating the pathological involvement of the immune system in type 2 diabetes is examined, together with the role of potential treatment modalities targeting the immune system in the management of type 2 diabetes.

Original languageEnglish
Pages (from-to)147-156
Number of pages10
JournalMinerva endocrinologica
Issue number2
Publication statusPublished - 1 Jun 2011



  • Adipokines
  • Cytokines
  • Diabetes mellitus
  • Inflammation
  • Type 2

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this